[go: up one dir, main page]

NO20031332D0 - Arylalkan-sulfonamider med endothelin-antagonistaktivitet - Google Patents

Arylalkan-sulfonamider med endothelin-antagonistaktivitet

Info

Publication number
NO20031332D0
NO20031332D0 NO20031332A NO20031332A NO20031332D0 NO 20031332 D0 NO20031332 D0 NO 20031332D0 NO 20031332 A NO20031332 A NO 20031332A NO 20031332 A NO20031332 A NO 20031332A NO 20031332 D0 NO20031332 D0 NO 20031332D0
Authority
NO
Norway
Prior art keywords
arylalkanesulfonamides
antagonist activity
endothelin antagonist
endothelin
activity
Prior art date
Application number
NO20031332A
Other languages
English (en)
Other versions
NO20031332L (no
Inventor
Thomas Weller
Martin Bolli
Christoph Boss
Martine Clozel
Walter Fischli
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20031332D0 publication Critical patent/NO20031332D0/no
Publication of NO20031332L publication Critical patent/NO20031332L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20031332A 2000-09-25 2003-03-24 Arylalkan-sulfonamider med endothelin-antagonistaktivitet NO20031332L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0009327 2000-09-25
PCT/EP2001/009894 WO2002024665A1 (en) 2000-09-25 2001-08-28 Arylalkane-sulfonamides having endothelin-antagonist activity

Publications (2)

Publication Number Publication Date
NO20031332D0 true NO20031332D0 (no) 2003-03-24
NO20031332L NO20031332L (no) 2003-03-24

Family

ID=8164105

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031332A NO20031332L (no) 2000-09-25 2003-03-24 Arylalkan-sulfonamider med endothelin-antagonistaktivitet

Country Status (18)

Country Link
US (1) US7091201B2 (no)
JP (1) JP2004509874A (no)
KR (1) KR100835770B1 (no)
CN (1) CN1326841C (no)
AR (1) AR032896A1 (no)
AT (1) ATE446289T1 (no)
AU (2) AU1217102A (no)
BR (1) BR0114082A (no)
CA (1) CA2423351C (no)
DE (1) DE60140263D1 (no)
ES (1) ES2333409T3 (no)
HU (1) HUP0303364A3 (no)
IL (1) IL154364A0 (no)
MX (1) MXPA03001991A (no)
NO (1) NO20031332L (no)
NZ (1) NZ524172A (no)
WO (1) WO2002024665A1 (no)
ZA (1) ZA200302292B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
US7482355B2 (en) 2002-08-24 2009-01-27 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
PL1725540T3 (pl) 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopirymidyny jako antagoniści p2x3 i p2x2/3
EP1809624B1 (en) 2004-08-28 2013-11-20 AstraZeneca AB Pyrimidine sulphonamide derivatives as chemokine receptor modulators
WO2007025899A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
BRPI0615613A2 (pt) 2005-09-01 2009-05-19 Hoffmann La Roche diaminopirimidinas como moduladores de p2x3 e p3x2/3
US9181231B2 (en) * 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
CN103864701B (zh) * 2014-03-10 2016-08-24 常熟市金申医化制品有限责任公司 4-磺胺-5-甲氧基-6-氯嘧啶的制备方法
BR112021005986A2 (pt) 2018-10-23 2021-06-29 Step Pharma S.A.S. derivados de aminopirimidina como inibidores de ctps1
CN114008039B (zh) * 2019-06-04 2024-01-16 斯泰普制药股份公司 作为人ctps1抑制剂用于治疗增殖性疾病的化合物
WO2020245665A1 (en) * 2019-06-04 2020-12-10 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1549494A (no) 1967-10-31 1968-12-13
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
JP2790065B2 (ja) * 1993-12-17 1998-08-27 田辺製薬株式会社 ベンゼンスルホンアミド誘導体及びその製法
US5837708A (en) * 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
JP3013752B2 (ja) * 1995-05-16 2000-02-28 田辺製薬株式会社 スルホンアミド誘導体
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
JP3067131B2 (ja) * 1995-06-16 2000-07-17 田辺製薬株式会社 医薬組成物
EP0882719B1 (en) * 1995-12-20 2001-05-16 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
JP3116347B2 (ja) * 1996-11-13 2000-12-11 田辺製薬株式会社 医薬組成物
AU8035698A (en) * 1997-06-19 1999-01-04 Yamanouchi Pharmaceutical Co., Ltd. Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same
JPH11343239A (ja) * 1998-03-31 1999-12-14 Tanabe Seiyaku Co Ltd 排尿障害の予防・治療剤

Also Published As

Publication number Publication date
JP2004509874A (ja) 2004-04-02
IL154364A0 (en) 2003-09-17
CN1633418A (zh) 2005-06-29
MXPA03001991A (es) 2003-06-24
NZ524172A (en) 2004-09-24
ZA200302292B (en) 2004-06-30
HUP0303364A3 (en) 2004-04-28
AU1217102A (en) 2002-04-02
CA2423351C (en) 2010-12-21
CN1326841C (zh) 2007-07-18
WO2002024665A8 (en) 2002-06-06
HUP0303364A2 (hu) 2004-03-01
CA2423351A1 (en) 2002-03-28
BR0114082A (pt) 2003-07-22
ATE446289T1 (de) 2009-11-15
US20040102464A1 (en) 2004-05-27
NO20031332L (no) 2003-03-24
AU2002212171B2 (en) 2006-12-14
KR100835770B1 (ko) 2008-06-09
KR20030029979A (ko) 2003-04-16
DE60140263D1 (de) 2009-12-03
AR032896A1 (es) 2003-12-03
ES2333409T3 (es) 2010-02-22
US7091201B2 (en) 2006-08-15
WO2002024665A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
DK1303496T3 (da) Pyrimidinderivater
PT1204663E (pt) Novos compostos espiro com actividade antagonista do neuropeptido y
NO2013018I1 (no) Avanafil
NO20000715L (no) Brennerkonstruksjon
NO20030795D0 (no) Kinazolinderivater
DE60239828D1 (de) Ür
PT1199054E (pt) Utensilio de liquefractura
NO20031332D0 (no) Arylalkan-sulfonamider med endothelin-antagonistaktivitet
DE50105757D1 (de) Geschirrspüler
NO20032291D0 (no) Pyrimidinderivater
SE0001918L (sv) Aktivitetsindikerande pilot
DE60103797D1 (de) Befestigungselement
DE50103720D1 (de) Befestigungselement
ATA21332000A (de) Möbel
DK1246828T3 (da) Benzosulfoner med calciummantagonist-aktivitet
AR028422A1 (es) Indanilimizadoles policeclicos nuevos con actividad adrencrgica alfa2
NO20000753D0 (no) Aktivitetsinnretning
ITRM20000220A0 (it) Cinnamilidenidrazide isonicotinica c15h13n3o
SE0000007D0 (sv) House-Net med Adapter
DE50004927D1 (de) Sitzmöbel
IT250092Y1 (it) Struttura di sedia
SE0000079D0 (sv) Gardinstång
FI4755U1 (fi) Työtuoli
SE0004363D0 (sv) New use
SE0000799D0 (sv) New use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application